Critical Care Medicine:
Laboratory diagnosis of 2009 H1N1 influenza A virus
Boggild, Andrea K. MD; McGeer, Allison J. MD
From Department of Infection Control (AKB, AJM), Mount Sinai Hospital, Toronto, Ontario; Tropical Disease Unit (AKB), Division of Infectious Diseases, UHN-Toronto General Hospital, Toronto, Ontario; Department of Microbiology (AJM), Mount Sinai Hospital, Toronto, Ontario; Department of Laboratory Medicine & Pathobiology (AJM), University of Toronto, Ontario.
The authors have not disclosed any potential conflicts of interest.
For information regarding this article, E-mail: email@example.com
The emergence of 2009 pandemic influenza H1N1 has necessarily led to the rapid evolution of sensitive, specific, and high-throughput molecular diagnostic assays for this virus at the same time that clinical laboratories attempt to cope with increasing demands in the setting of resource limitations. This situation has given rise to testing algorithms focusing on priority, clinical relevance, and appropriate surveillance. We describe the current state of understanding around diagnostic testing and laboratory detection of 2009 H1N1 influenza A virus.
Since the emergence of 2009 H1N1 in the spring of 2009, laboratory detection methods have evolved rapidly to meet the ongoing challenges posed by this pandemic strain of novel influenza A virus. Early challenges of identifying the nature of the virus (1) and the timely provision of influenza A subtyping information have since been replaced with the need for algorithmic approaches to diagnostic testing (2), lest laboratories become further overwhelmed with clinical specimens given the widespread circulation of 2009 H1N1. Accordingly, laboratories have sought rapid, sensitive, specific, and scalable high-throughput detection methods to better-cope with the demands of population-level diagnostic testing inherent to a pandemic situation (3). This article reviews the current state of understanding surrounding the approach to diagnostic testing and laboratory detection of 2009 H1N1 influenza A virus.
Who Should Be Tested for Diagnosis of 2009 H1N1 Infection?
For a number of reasons, not the least of which being limited laboratory resources, widespread confirmatory diagnostic testing for 2009 H1N1 has not been a viable strategy since early in the pandemic. Rather, many public health bodies, governments, and institutions have recommended confirmatory diagnostic testing only for patients with influenza-like illness warranting admission to hospital, those with underlying risk factors for complicated infection such as pregnancy, those with worsening clinical status, or those in institutional or other outbreak situations (4, 5). Because most patients with 2009 H1N1 will recover at home uneventfully without antiviral therapy, confirmatory diagnostic testing adds little to their management. Testing should be performed only in circumstances in which the results will alter clinical or infection control management, or as needed for public health surveillance purposes.
The performance characteristics of diagnostic assays for 2009 H1N1 stratified by clinical and demographic data, such as age, gender, severity of illness, and management setting, are scarce. In their evaluation of several testing methods for 2009 H1N1 during the New York City outbreak, Ginocchio et al (2) demonstrated excellent performance of their reverse-transcription polymerase chain reaction (RT-PCR) assay across patient ages ranging from 2 wks to 97 yrs. Sabetta et al (6) demonstrated differential performance of a rapid influenza diagnostic test (RIDT) in patients with RT-PCR-positive nasopharyngeal swabs based on clinical symptoms: those with a Centers for Disease Control and Prevention-defined influenza-like illness (fever plus cough or sore throat) were 50% more likely to have positive RIDT results compared to those without. Finally, in their study of 84 2009 H1N1 RT-PCR-positive specimens, Vasoo et al (7) found that both inpatient or emergency department status were predictive of positive RIDT results, perhaps suggesting that more severely ill patients shed higher quantities of more virus, and thus are more likely to test positive in low-sensitivity diagnostic tests, such as the RIDT. In support of this hypothesis, higher median fluorescence intensity on the RT-PCR assay was also predictive of RIDT positivity. However, other factors thought to be associated with shedding of increased concentrations of virus, such as younger age and shorter duration of symptoms, were not predictive of RIDT positivity in this study (7).
In patients requiring hospitalization or intensive care unit (ICU) admission, several studies have demonstrated that clinical symptoms are poor predictors of a diagnosis of seasonal influenza; only laboratory testing is adequate to diagnose influenza (8–11). This is a general truth about infectious agents causing primarily respiratory illness, and these conclusions are likely true of pandemic influenza as well. Based on what is known about the clinical features of 2009 pandemic H1N1 influenza, ICU clinicians should be testing all patients suspected of having a respiratory infection, patients admitted with exacerbations of underlying lung diseases such as chronic obstructive pulmonary disease or asthma, and all patients with a febrile illness of uncertain origin. Influenza can also cause myocarditis and encephalopathy and should be considered in the differential diagnosis of these conditions during periods of increased pandemic activity.
During Illness, When Should Testing for 2009 H1N1 Be Performed?
Comprehensive data on the optimal timing of specimen collection for the diagnosis of 2009 H1N1 are limited. Viral titers in respiratory specimens are highest during the first 3 days of illness; however, it is recognized that children typically shed more virus for more prolonged periods than adults (12). Through quantitative RT-PCR analysis of serially collected nasopharyngeal swabs, we have found that viral shedding appears to be greatest on the first and second day of illness, declining significantly thereafter (13, Smieja et al unpublished data, Scientific Programme Supplement, Late Breaker Abstracts, p. 4). However, in a small proportion of patients, viral detection in those not receiving antivirals persists up to 9 or 10 days after the onset of symptoms (13–15). In their convenience sample of 84 2009 H1N1 RT-PCR–positive specimens, Vasoo et al (7) found that the mean interval between onset of symptoms and specimen collection was 2.8 days (range, 1–9 days). A full three-quarters of patients in their study presented for specimen collection within 3 days of symptom onset (7). Interestingly, in their study of two school outbreaks of 2009 H1N1, Sabetta et al (6) demonstrated that patients with specimens collected within 36 hrs of symptom onset were no more likely to have a positive RIDT result than those whose specimens were collected >36 hrs after symptom onset, perhaps illustrating that a 36-hr cutoff is still well within the timeframe of peak viral shedding.
Other factors that may influence the quantity of virus in a clinical specimen, and theoretically affect the test performance, include the type of specimen collected and pre-analytical transport and storage (12). Accordingly, optimization of the timing, transportation, and storage of clinical specimens would be expected to improve the diagnostic yield, especially using lower-sensitivity tests such as RIDT or direct fluorescent antigen (DFA).
In patients requiring admission to the ICU, clinical judgment is required to determine whether a second test is warranted to assess response to therapy and need for ongoing isolation precautions. In patients who are improving, repeat testing is not helpful, and additional precautions for prevention of transmission of infection can be based on empirical protocols (e.g., precautions until 7 days after the onset of symptoms). However, optimal management for patients with persisting or worsening symptoms is more difficult to determine. In patients who are apparently responding to therapy, PCR often will remain positive until after day 7, and occasionally for longer (10, 15). Anecdotal experience suggests the viral culture is rarely positive in this circumstance (10), but viral culture results require several days. Deterioration inpatient condition may be attributable to selection for viral resistance, as has been documented with other influenzas (16) and pandemic H1N1 (17, 18), but is more likely to be to a complicating hospital-acquired disease, such as ventilator-associated pneumonia or pulmonary embolus. In this setting, it seems reasonable to follow PCR at 3- to 4-day intervals until either PCR is negative or clinical improvement is apparent. Quantitative PCR is useful, if available, because viral concentrations will increase in those with evolving viral resistance on therapy (16) or in severely compromised patients who cannot control viral replication even in the presence of specific antiviral therapy (18–21) but remain low and stable in patients with deterioration attributable to other causes.
What Specimen Should Be Collected for Detection of 2009 H1N1?
The ideal clinical specimens for the detection of 2009 H1N1 are thought to be nasopharyngeal swabs or aspirates (4, 5, 22). These swabs have a synthetic tip made of polyester or Dacron, and a plastic or aluminum shaft. They are packaged with or without viral transport media and are sterile. Throat swabs or other swabs with cotton tips or wooden shafts should not be used (5, 22). Nasal aspirates, nasal swabs, and oropharyngeal swabs also may be used for specimen collection, although these are not preferred (5, 22). Expectorated sputum may be used for diagnosis; for patients who are intubated, bronchoalveolar lavage or endotracheal aspirates are acceptable. Eye swabs and stool are not considered appropriate specimens for the detection of 2009 H1N1 and will likely be rejected by the testing laboratory. Sterile tubes of pink viral transport medium containing buffer, protein, antibiotics, and antifungals should be brought to the bedside for specimen collection if not packaged along with the nasopharyngeal swab. Detailed video instructions on how to collect a nasopharyngeal swab are freely available (23, http://content.nejm.org/cgi/content/full/NEJMe0903992/DC1). It is important to remember that careful hand hygiene should be performed and appropriate barrier precautions used during the specimen collection process (5, 22). Once the specimen is collected and placed into the viral transport medium, it should be sent to the laboratory immediately (22).
What Test Should Be Used for Detection of 2009 H1N1?
Four main platforms form the backbone of influenza testing in the clinical laboratory: rapid antigen testing (RIDT), DFA testing, viral culture, and molecular testing such as RT-PCR. Serologic testing offers little in the diagnosis of influenza. Each method has inherent limitations and advantages for influenza testing. RIDT provide a rapid turnaround time and require little technical expertise, but they lack sensitivity compared to viral culture and molecular methods (2, 24) and do not distinguish between the various types of influenza A (e.g., 2009 H1N1 vs. seasonal H1N1 vs. seasonal H3N2) (2, 6, 7, 12, 24). Viral culture and DFA are more sensitive (2) but require technical expertise to perform and have greater laboratory infrastructural requirements. Both DFA and viral culture have the added of advantage of identifying other respiratory viruses that commonly circulate during influenza season, such as parainfluenza, adenovirus, respiratory syncytial virus, and human metapneumovirus (2), although neither DFA nor viral culture can distinguish subtypes of influenza A. Furthermore, both DFA and viral culture require expertise in microscopy, and viral culture has a long turnaround time. The most sensitive test is RT-PCR. The only platform that can specifically and reliably distinguish 2009 H1N1 from other influenza A viruses is molecular testing, usually using an RT-PCR assay.
The Table 1 summarizes the reported performance characteristics of various diagnostic tests used to detect 2009 H1N1 from clinical specimens. The performance of RIDT demonstrated interassay and interstudy variability, with sensitivities for detecting 2009 H1N1 ranging from 17.8% to 53.4% (Table 1). While most RIDT had reasonable positive predictive values, their poor negative predictive values underscore the recommendation of the Centers for Disease Control and Prevention to avoid clinical decision-making during the pandemic based on negative RIDT assays (25). Again, RIDT cannot distinguish 2009 H1N1 from any other circulating influenza A strain. Only one study reported the performance characteristics of DFA for 2009 H1N1, which appear to be comparable or superior to those of the RIDT (Table 1). R-Mix viral culture performed well compared to RIDT and DFA, with a sensitivity of 88.9% and specificity of 100% (2). Although viral culture remains the reference standard for influenza diagnosis, both the increased time to results (2–7 days) and the need for downstream subtyping of a positive culture render it much less attractive and efficient than nucleic acid-based tests, most of which can be multiplexed and yield a specific result in a single step. Thus, the rapid, sensitive, and specific nucleic acid testing methods are clearly the optimal choice for diagnosis of the 2009 pandemic strain of H1N1.
On the emergence of 2009 H1N1, such authoritative bodies as the Centers for Disease Control and Prevention, World Health Organization, and Public Health Agency of Canada acted quickly to provide detailed methods for RT-PCR detection of the virus (26–28), which had been identified in other conventional molecular assays as “influenza A unsubtypeable.” A common approach for the confirmation and subtyping of influenza A before the emergence of the pandemic strain would be to perform an initial screening RIDT, DFA, culture, or RT-PCR targeting influenza A matrix gene (the latter of which would detect all influenza A subtypes), followed by an RT-PCR assay specific for different influenza A hemagglutinin genes, which would discriminate between pandemic H1, seasonal H3, and seasonal H1 viruses (29). The US Food and Drug Administration-approved respiratory virus panel is a multiplex RT-PCR assay with a microfluidic array detection on the Luminex 100 (Luminex, Austin, TX) instrument that detects ≥10 viruses, including parainfluenza 1 through 3, respiratory syncytial virus, adenovirus, human metapneumovirus, and influenzas A and B (30–32); it is another molecular approach to detecting and subtyping influenza A. In addition to detecting the influenza A matrix gene, it will discriminate between seasonal H3 and H1 based on hemagglutinin sequences; 2009 H1N1 is identified in this assay as an influenza A that fails to subtype as either seasonal H1 or seasonal H3. The manufacturers of this system, and other commercial systems detecting influenza by PCR, are working on the development of 2009 H1N1-specific assays (3, 26–28).
In addition to 2009 H1N1 RT-PCR protocols published by authoritative bodies, several groups have designed their own in-house RT-PCR assays based on available GenBank sequences (http://www.ncbi.nih.gov/genomes/FLU/SwineFlu.html) and have published their verification results (3, 24, 33–36). Pabbaraju et al investigated the performance characteristics of three in-house RT-PCR assays (one specific for 2009 H1N1 hemagglutinin and two specific for 2009 H1N1 matrix gene) and compared them to the published Centers for Disease Control and Prevention 2009 H1N1 hemagglutinin-specific assay (28), a 2009 H1N1 hemagglutinin-specific assay from the National Microbiology Laboratory in Winnipeg (3), and two matrix gene assays that would detect all influenza A viruses (29, 37). The sensitivities of the three in-house assays demonstrated equal or superior performance compared to the Centers for Disease Control and Prevention 2009 H1N1 hemagglutinin-specific assay (Table) (3, 38). They also had good specificity with no cross-reactivity with common respiratory viruses and comparable analytic sensitivity (limits of viral detection) compared to other reported quantitative assays (3).
In addition to qualitative RT-PCR assays, quantitative methods increasingly are being adapted (9, 33, 34), although more for surveillance and investigational purposes rather than for initial clinical diagnosis. Both qualitative and quantitative RT-PCR assays are reportedly up to 500-times more sensitive than viral culture (33), with quantitative detection limits of approximately 5000 viral genome copies per sample (33, 34). It has been reported, and has been our experience, that qualitative RT-PCR has greater sensitivity than quantitative assays (33, Smieja et al, unpublished data); however, efforts to optimize the performance of quantitative RT-PCR are being undertaken.
In summary, the most common diagnostic algorithms to be used when seasonal influenza may be co-circulating with 2009 H1N1 includes either a commercial RT-PCR that subtypes influenza A or a pan-influenza A matrix gene RT-PCR plus RT-PCR differentiating between H1 and H3 subtypes, followed by one of the 2009 H1N1-specific assays targeting matrix, nucleoprotein, or neuraminidase genes (26–28). In the absence of other circulating influenza (i.e., outside of regular influenza season), subtyping may be deemed unnecessary, thus simplifying the algorithm to include any test that detects influenza A by PCR. Nucleic acid- based approaches to the detection of 2009 H1N1 are clearly superior to conventional nonmolecular-based tests for influenza (such as RIDT, DFA, and culture) because of their rapidity, excellent sensitivity, specificity, scalability, and ability to distinguish between seasonal and pandemic influenza A, often in a single step. Although RIDT and DFA are rapid and inexpensive, they are insensitive and do not differentiate among influenza A subtypes.
1.Shinde V, Bridges CB, Uyeki TM, et al: Triple-reassortant swine influenza A (H1) in humans in the United States, 2005–2009. N Eng J Med 2009; 360:2616–2625
2.Ginocchio CC, Zhang F, Manji R, et al: Evaluation of multiple test methods for the detection of the novel 2009 influenza A (H1N1) during the New York City outbreak. J Clin Virol 2009; 45:191–195
3.Pabbaraju K, Wong S, Wong AA, et al: Design and validation of real-time reverse transcription-PCR assays for detection of pandemic (H1N1) 2009 virus. J Clin Micro 2009; 47:3454–3460
6.Sabetta JR, Smardin J, Burns L, et al: Performance of rapid influenza diagnostic tests during two school outbreaks of 2009 pandemic influenza A (H1N1) virus infection—Connecticut 2009. MMWR Morbid Mortal Wkly Rep 2009; 58:1029–1032
7.Vasoo S, Stevens J, Singh K: Rapid antigen tests for diagnosis of pandemic (swine) influenza A/H1N1. Clin Infect Dis 2009; 49:1090–1093
8.van den Dool C, Hak E, Wallinga J, et al: Symptoms of influenza virus infection in hospitalized patients. Infect Contr Hosp Epidemiol 2008; 29:314–319
9.Babcock H, Merz L, Dubberke R, et al: Case-control study of clinical features of influenza in hospitalized patients. Infect Contr Hosp Epidemiol 2008; 29:921–926
10.Lee N, Chan PKS, Hui DSC, et al: Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J Infect Dis 2009; 200:492–500
11.Ison MG: Influenza in hospitalized adults: Gaining insight into a significant problem. J Infect Dis 2009; 200:485–488
12.Balish A, Warnes CM, Wu K, et al: Evaluation of rapid influenza diagnostic tests for detection of novel influenza A (H1N1) virus—United States, 2009. MMWR Morbid Mortal Wkly Rep 2009; 58:826–829
13.Smieja M, Petrich A, Luinstra K, et al: Viral load testing of influenza A/California 2009 (H1N1, “Swine Flu”) in serial nasopharyngeal or self-collected nasal swabs. Presented at the 26th Annual International Congress on Chemotherapy and Infection, Toronto, Ontario, June 2009, Scientific Programme Supplement, Late Breaker Abstracts, P. 4.
14.De Serres G, Roulian L, Hamelin ME, et al: Shedding of novel 2009 pandemic H1N1 (nH1N1) virus at one week post illness onset. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 2009; Abstract K-1918a
15.Lye D, Chow A, Tan A, et al: Oseltamivir therapy and viral shedding in pandemic (H1N1) 2009. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 2009; Abstract V-1269c
16.de Jong M, Thanh TT, Khanh TH, et al: Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 2005; 353:2667–2672
17.World Health Organization: Oseltamivir-resistant pandemic (H1N1) 2009 influenza virus, October 2009. Wkly Epidemiol Rec 2009; 44:453–468
18.Centers for Disease Control and Prevention: Oseltamivir-resistant novel influenza A (H1N1) virus infection in two immunosuppressed patients. MMWR Morbid Mortal Wkly Rep 2009; 58:893–895
19.Klimov AI, Rocha E, Hayden FG, et al: Prolonged shedding of amantadine-resistant influenzae A viruses by immunodeficient patients: Detection by polymerase chain reaction-restriction analysis. J Infect Dis 1995; 172:1352–1355
20.Ison MG, Gubareva LV, Atmar RL, et al: Recovery of drug-resistant influenza virus from immunocompromised patients: A case series. J Infect Dis 2006; 193:760–764
21.Weinstock DM, Gubareva LV, Zuccotti G: Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient. N Engl J Med 2003; 27:348:867–868
22.Centers for Disease Control and Prevention: Interim Guidance on specimen collection, processing, and testing for patients with suspected novel influenza A (H1N1) virus infection. Atlanta, GA: US Department of Health and Human Services, CDC, 2009. Available at http://www.cdc.gov/h1n1flu/specimencollection.htm
. Accessed November 12, 2009
23.Baden LR, Drazen JM, Kritek PA, et al: H1N1 influenza A disease information for health prrofessionals. N Engl J Med 2009; 360:2666–2667
24.Kok J, Blyth CC, Foo H, et al: Comparison of a rapid antigen test with nucleic acid testing during co-circulation of pandemic influenza A/H1N1 2009 and seasonal influenza A/H3N2. J Clin Microbiol 2010; 48:290–291
25.Centers for Disease Control and Prevention: Interim guidance for the detection of novel influenza A virus using rapid influenza diagnostic tests. Atlanta, GA: US Department of Health and Human Services, CDC, 2009. Available at http://www.cdc.gov/h1n1flu/guidance/rapid_testing.htm
. Accessed November 11, 2009
27.Public Health Agency of Canada: RT-PCR protocol for swine H1N1 influenza, April 2009. Ottawa, Ontario: National Microbiology Laboratory, PHAC; 2009: 1–7
28.Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team, Dawood FS, Jain S, Finelli L, et al: Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009; 360:2605–2615
29.Centers for Disease Control and Prevention: CDC real time RTPCR (rRTPCR) protocol for detection and characterization of influenza (version 2006), Ref. #1-007-05. Atlanta, GA: Centers for Disease Control and Prevention; 2006
30.Krunic N, Yager TD, Himsworth D, et al: xTAG RVP assay: Analytical and clinical performance. J Clin Virol 2007; 40(Suppl 1):S39–S46
31.Merante F, Yaghoubian S, Janeczcko R: Principles of the xTAG respiratory viral panel assay (RVP assay). J Clin Virol 2007; 40(Suppl 1):S31–S35
32.Mahony JB, Hatchette T, Ojkic D, et al: Multiplex PCR tests sentinel the appearance of pandemic influenza viruses including H1N1 swine influenza. J Clin Virol 2009; 45:200–202
33.Poon LLM, Chan KH, Smith GJ, et al: Molecular detection of a novel human influenza (H1N1) of pandemic potential by conventional and real-time quantitative RT-PCR assays. Clin Chem 2009; 55:1555–1558
34.Wang R, Sheng Z-M, Taubenberger JK: Detection of novel (swine origin) H1N1 influenza A virus by quantitative real-time reverse transcription-PCR. J Clin Micro 2009; 47:2675–2677
35.Whiley DM, Bialasiewicz S, Bletchly C, et al: Detection of novel influenza A (H1N1) virus by real-time RT-PCR. J Clin Virol 2009; 45:203–204
36.Carr MJ, Gunson R, Maclean A, et al: Development of a real-time RT-PCR for the detection of swine-lineage influenza A (H1N1) virus infections. J Clin Virol 2009; 45:196–199
37.Fouchier RAM, Bestebroer TM, Herfst S, et al: Detection of influenza A viruses from different species by PCR amplification of conserved sequences in the matrix gene. J Clin Microbiol 2000; 38:4096–4101
38.Faix DJ, Sherman SS, Waterman SH: Rapid-test sensitivity for novel swine-origin influenza A (H1N1) virus in humans. N Eng J Med 2009; 361:728–729
This article has been cited 3 time(s).
Plos OneA Host Transcriptional Signature for Presymptomatic Detection of Infection in Humans Exposed to Influenza H1N1 or H3N2Plos One
Journal of Exposure Science and Environmental EpidemiologyExposure science for viral diseases: 2009 H1N1 pandemic influenza virusJournal of Exposure Science and Environmental Epidemiology
Journal of Clinical MicrobiologyEvaluation of Twelve Real-Time Reverse Transcriptase PCR Primer-Probe Sets for Detection of Pandemic Influenza A/H1N1 2009 VirusJournal of Clinical Microbiology
emerging infections; influenza A; polymerase chain reaction; rapid influenza diagnostic test; sensitivity; specificity; swine-origin influenza
© 2010 by the Society of Critical Care Medicine and Lippincott Williams & Wilkins
Highlight selected keywords in the article text.